T1780L
|
|
|
|
Parecoxib is a cyclooxygenase-2 inhibitor used for the short-term treatment of postoperative pain in adults. Parecoxib is a water-soluble and injectable prodrug of valdecoxib. Parecoxib is a COX2 selective inhibitor in the same category as celecoxib and r |
T80651
|
|
|
Lipoxygenase
|
(-)-Bornyl ferulate,作为5-脂氧合酶和COX抑制剂,其IC50值分别为10.4 μM和12.0 μM。 |
T62142
|
|
|
|
COX-2-IN-17 是一种有效的、具有血脑屏障通透性的 COX-2(环氧化酶 -2) 抑制剂 (IC50: 0.02 μM),具有抗炎和镇痛活性。 |
T75625
|
|
|
|
Axinelline A 是一种有效的 COX 抑制剂,对 COX-2和 COX-1的IC50分别为 2.22 μΜ 和 8.89 μM。Axinelline A 显示抗炎活性。 |
T15825
|
|
|
Retinoid Receptor
|
LY 178002 is an effective inhibitor of 5-lipoxygenase (5-LPO), phospholipase A2 (IC50: 0.6 μM for 5-lipoxygenase). LY 178002 also inhibits cellular production of LTB4 by human polymorphonuclear leukocytes and displays relatively weak inhibition on cycloox |
T38194
|
|
|
|
Prostaglandin E3 (PGE3) is formed via the cyclooxygenase (COX) metabolism of eicosapentaenoic acid. [1] In human ocular tissue, it comprises 2.4% of the COX products formed. [1] When applied to the eyes of a rabbit, a 1 µg dose of PGE3 decreases intraocular pressure from 21 mmHg to about 17 mmHg.[2] |
T62296
|
|
|
|
MMV688844 是一种脓肿分歧杆菌 (Mabs) DNA 促旋酶的有效抑制剂 (IC50: 2 μM),可作用于脓肿分歧杆菌 bamboo 菌株 (MIC50: 12 μM)。MMV688844 能够用于研究抗菌。 |
T68847
|
|
|
|
Aspirin calcium is the prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5) |
T62350
|
|
|
|
XO/COX/LOX-IN-1 是一种黄嘌呤氧化酶/环氧酶/脂氧合酶 XO/COX/LOX 的有效抑制剂。XO/COX/LOX-IN-1 能够用于研究炎症、癌症以及代谢性疾病。 |
T70718
|
|
|
|
CR6086 is a novel, potent EP4 antagonist showing favourable immunomodulatory properties, striking DMARD effects in rodents, and anti-inflammatory activity targeted to immune-mediated inflammatory diseases and distinct from the general effects of cyclooxygenase inhibitors. CR6086 showed selectivity and high affinity for the human EP4 receptor (Ki = 16.6 nM) and functioned as a pure antagonist (half-maximal inhibitory concentration, 22 nM) on PGE2-stimulated cAMP production. |